Table 1 Patient demographics, medications and renal status at the time of the urine collection.
| Â | Â | Focal segmental glomerulosclerosis | Proliferative LN (class III or IV) | Pure membranous LN (class V) | |||
|---|---|---|---|---|---|---|---|
| Â | Â | n of 10 (%) | Median (Range) | n of 7 (%) | Median (Range) | n of 7 (%) | Median (Range) |
Females | Â | 3 (33%) | Â | 4/7 (57%) | Â | 5/7 (71%) | Â |
Race | Black | 2/10 (20%) | Â | 3/7 (42%) | Â | 3/7 (42%) | Â |
| Â | White | 5/10 (50%) | Â | 2/7 (29%) | Â | 2/7 (29%) | Â |
|  | Other | 3/10 (30%)* |  | 2/7 (29%)†|  | 3/7 (43%)** |  |
Medications | Oral prednisone | 4/10 (40%) | Â | 7/7 (100%) | Â | 4/7 (57%) | Â |
| Â | Mycophenolate mofetil | 5/10 (50%) | Â | 3/7 (43%) | Â | 5/7 (71%) | Â |
| Â | Cyclophosphamide | - | Â | 2/7 (29%) | Â | 1/7 (14%) | Â |
| Â | Angiotensin blocking agent | 9/10 (90%) | Â | 2/7 (29%) | Â | 6/7 (86%) | Â |
Kidney Status | GFR < 60 ml/min/m2 | 4/10 (40%) | Â | 1/7 (14%) | Â | 1/7 (14%) | Â |
| Â | Protein: creatinine ratio > 0.5 | 5/5 (100%) | Â | 7/7 (100%) | Â | 7/7 (100%) | Â |
| Â | Renal SDI score > 0Â¥ | - | Â | 0/3 | Â | 1/4 (25%) | Â |
|  | Renal SLEDAI score‡ | - |  |  | 4 (0-16) |  | 8 (4-12) |
| Â | Presence of anti double-stranded-dsDNA | - | Â | 7/7 (100%) | Â | 4/7 (67%) | Â |